A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease - Harada, Katsuya; Nakato, Kazuhiro; Yarimizu, Junko; Yamazaki, Mayako; Morita, Masahiko; Takahashi, Shinji; Aota, Masaki; Saita, Kyoko; Doihara, Hitoshi; Sato, Yuichiro; Yamaji, Takayuki; Ni, Keni; et al. (European journal of pharmacology, 2012)
Keywords: administration & dosage; Administration, Oral; Alzheimer disease; Alzheimer Disease - drug therapy; Alzheimer Disease - physiopathology; Alzheimer's disease; Animal model; animal models; Animals; antagonists & inhibitors; brain; Brain - metabolism; cognition; Cognition Disorders; Cognition Disorders - drug therapy; Cognition Disorders - etiology; Cognition Disorders - physiopathology; Cognitive impairment; Disease Models, Animal; Dizocilpine Maleate; Dizocilpine Maleate - toxicity; Dose-Response Relationship, Drug; drug therapy; etiology; Female; Glycine Plasma Membrane Transport Proteins; Glycine Plasma Membrane Transport Proteins - antagonists & inhibitors; Glycine transporter; Humans; Inhibitory Concentration 50; Male; memory; Memory Disorders; Memory Disorders - drug therapy; Memory Disorders - physiopathology; metabolism; Mice; N-methyl-d-aspartate (NMDA); oral administration; Oxadiazoles; Oxadiazoles - administration & dosage; Oxadiazoles - pharmacokinetics; Oxadiazoles - pharmacology; Permeability; pharmacokinetics; pharmacology; physiopathology; Rats; Rats, Wistar; receptors; Schizophrenia; Schizophrenia - drug therapy; Schizophrenia - physiopathology; toxicity; Triazoles; Triazoles - administration & dosage; Triazoles - pharmacokinetics; Triazoles - pharmacology; Schizophrenia; Animal model; N-methyl-d-aspartate (NMDA); Glycine transporter; Alzheimer's disease; Cognitive impairment